Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1176-1180

  Di Fabio, Romano ^a   Alvaro, Giuseppe ^a   Bertani, Barbara ^a   Donati, Daniele ^a   Pizzi, Domenica Maria ^a   Gentile, Gabriella ^a   Pentassuglia, Giorgio ^a   Giacobbe, Simone ^a   Spada, Simone ^a   Ratti, Emiliangelo ^a   Corsi, Mauro ^a   Quartaroli, Mauro ^a   Barnaby, Robert J ^a   Vitulli, Giovanni ^a  

^a GSK   (Italy)

Author keywords

Excitatory amino acids; Glycine antagonists; Pain

Indexed keywords

4,6 DICHLORO 3 (2 OXO 1 PHENYL 3 PYRROLIDINYLIDENEMETHYL) 1H INDOLE 2 CARBOXYLIC ACID; ANALGESIC AGENT; DIZOCILPINE; GAMMA LACTAM DERIVATIVE; GLYCINE RECEPTOR ANTAGONIST; HYDANTOIN DERIVATIVE; LACTIC ACID DERIVATIVE; LEWIS ACID; MORPHINE; QUINOLINE DERIVATIVE; SILANE DERIVATIVE; TRIFLUOROMETHANESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHIRALITY; CHRONIC PAIN; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; DRUG SYNTHESIS; HYPERALGESIA; IN VIVO STUDY; INFLAMMATION; MANNICH REACTION; NEUROPATHIC PAIN; NONHUMAN; POLYMERIZATION; RAT;

ANIMALS; BIOLOGICAL AVAILABILITY; DISEASE MODELS, ANIMAL; GLYCINE; HYDROQUINONES; HYPERALGESIA; INFLAMMATION; PAIN; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

ANIMALIA;

EID: 33846898549     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.12.022     Document Type: Article

References (35)

1. Choi D.W. Neuron 1 (1988) 623
2. Meldrum B., and Garthwaite J. Trends Pharmacol. 11 (1990) 379
3. Choi D.W. Prog. Brain. Res. 100 (1994) 47
4. Danysz W., Parsons C.G., and Bresnick I. Drug News Prospect. 8 (1996) 261
5. Wang S.J., and Yang T.T. Drug News Prospect. 18 (2005) 561
6. Woolf C.J. Nature 306 (1983) 686
7. Davies S.N., and Lodge D. Brain Res. 424 (1987) 402
8. Haley J.E., Sullivam A.F., and Dickenson A.H. Brain Res. 518 (1990) 218
9. Dickenson A.H. Trends Pharmacol. 11 (1990) 307
10. Woolf C.J., and Thompson S.W.N. Pain 44 (1991) 293
11. Woolf C.J. Pulmonary Pharmacol. 8 (1995) 161
12. Harris J.A., Corsi M., Quartaroli M., Arban R., and Bentivoglio M. Neuroscience 74 (1996) 7
13. Dickenson A.H., Chapman V., and Green G.M. Gen. Pharmacol. 28 (1997) 633
14. Parsons C.G. Eur. J. Pharmacol. 429 (2001) 71
15. Jessel, T. M.; Kelly, D. D. Pain and Analgesia. In Principles of Neural Science; Kandel, E. R., Schwartz, J. H., Jessell, T. H., Eds.; Appleton & Lange: 1991; pp 385-399.
16. Palfreyman M.G., and Baron M.B. Non-competitive NMDA Antagonists Acting at the Glycine Site. In: Meldrum B. (Ed). Excitatory Amino Acid Antagonists (1991), Blackwell, Oxford, England 101-129
17. Carter A.J. Drugs Future 17 (1992) 595
18. Leeson P.D., and Iversen L.L. J. Med. Chem. 37 (1994) 4053
19. Di Fabio R., Gaviraghi G., and Reggiani A. La Chim. l'Ind. 78 (1996) 283
20. Di Fabio R., Capelli A.M., Conti N., Cugola A., Feriani A., Gastaldi P., Gaviraghi G., Hewkin C.T., Micheli F., Missio A., Mugnaini M., Pecunioso A., Quaglia A.M., Ratti E., Rossi L., Tedesco G., Trist D.G., and Reggiani A. J. Med. Chem. 40 (1997) 841
21. Di Fabio R., Cugola A., Donati D., Feriani A., Gaviraghi G., Ratti E., Trist D.G., and Reggiani A. Drugs Future 23 (1998) 61
22. Dickenson A.H., and Aydar E. Neurosci. Lett. 121 (1991) 263
23. Millian M.J., and Seguin L. Neurosci. Lett. 178 (1994) 139
24. Quartaroli M., Carignani C., Dal Forno G., Mugnaini M., Ugolini A., Arban R., Bettelini L., Maraia G., Belardetti F., Reggiani A., Trist D.G., Ratti E., Di Fabio R., and Corsi M. J. Pharmacol. Exp. Ther. 290 (1999) 158
25. Di Fabio R., Conti N., Corsi M., Donati D., Gastaldi P., Gaviraghi G., Giacobbe S., Pentassuglia G., Quartaroli M., Ratti E., Trist D.G., and Ugolini A.R. Drugs Future 25 (2000) 137
26. For some structurally related glycine antagonists, see:. Di Fabio R., Tranquillini E., Bertani B., lvaro G., Micheli F., Sabbatini F., Pizzi M.D., Pentassuglia G., Pasquarello A., Messeri T., Donati D., Ratti E., Arban R., Dal Forno G., Reggiani A., and Barnaby R.J. Bioorg. Med. Chem. Lett. 13 (2003) 3863
27. DiFabio R., Alvaro G., Bertani B., and Giacobbe S. Can. J. Chem. 6 (2000) 78
28. Kishimoto H., Simon J.R., and Aprison M.H. J. Neurochem. 37 (1981) 1015
29. Di Fabio R., Alvaro G., Bertani B., Donati D., Giacobbe S., Marchioro C., Palma C., and Lynn S.M. J. Org. Chem. 67 (2002) 7319
30. Kobayashi S., Busujima T., and Nagayama S. Synlett 5 (1999) 545 and references herein enclosed
31. 3, as described by. Kobayashi S., and Nagayama S. J. Am. Chem. Soc. 120 (1998) 2985 The desired aldehyde has been obtained in good yield and the recovered microencapsulated Lewis acid was used again without significant loss of the catalytic activity
32. From preliminary experimental observations it seems that any kind of metal triflates, used in catalytic amount, is able to promote this addition reaction, independent of the nature of the metal used, namely alkaline earth metals, transition metals or lanthanide metals. This result might be explained based upon the non-nucleophilic nature of the triflate anion, and hence the stronger cationic character of the central metal, responsible for the activation of the catalytic cycle. Additional studies are ongoing to confirm these initial experimental observations and the outcome of this new exploration will be reported in due course.
33. Sivilotti L.G., Thompson S.W.N., and Woolf C.J. J. Neurophysiol. 69 (1993) 1621
34. For a detailed description of the experimental procedures used for the in vivo characterization of compound 2a both in the formalin model in mice and in the chronic constriction injury model in rats, see Ref. 24.
35. This research complied with national legislation and with company policy on the Care and Use of Animals and with related codes of practice.